{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T20:26:19Z","timestamp":1792787179093,"version":"4.5.0"},"reference-count":53,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2017,10,1]],"date-time":"2017-10-01T00:00:00Z","timestamp":1506816000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,3,15]],"date-time":"2017-03-15T00:00:00Z","timestamp":1489536000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000024","name":"Canadian Institutes of Health Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000038","name":"Natural Sciences and Engineering Research Council of Canada","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000038","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Kinsley Brotherton McLeod Endowment","id":[{"id":"https:\/\/ror.org\/0229evh14","id-type":"ROR","asserted-by":"crossref"}]},{"name":"Florence & George Heighway Endowment","id":[{"id":"https:\/\/ror.org\/0229evh14","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","molmetab.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Metabolism"],"published-print":{"date-parts":[[2017,10]]},"DOI":"10.1016\/j.molmet.2017.06.012","type":"journal-article","created":{"date-parts":[[2017,6,22]],"date-time":"2017-06-22T15:20:47Z","timestamp":1498144847000},"page":"1161-1172","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":32,"title":["Lipid nanoparticle delivery of glucagon receptor siRNA improves glucose homeostasis in mouse models of diabetes"],"prefix":"10.1016","volume":"6","author":[{"given":"Ursula H.","family":"Neumann","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica S.S.","family":"Ho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sam","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuen Yi C.","family":"Tam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pieter R.","family":"Cullis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy J.","family":"Kieffer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.molmet.2017.06.012_bib1","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1056\/NEJM197808312990901","article-title":"Hyperglucagonemia and its suppression. Importance in the metabolic control of diabetes","volume":"299","author":"Raskin","year":"1978","journal-title":"The New England Journal of Medicine"},{"key":"10.1016\/j.molmet.2017.06.012_bib2","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1007\/BF00400639","article-title":"Failure of glucagon suppression contributes to postprandial hyperglycaemia in IDDM","volume":"38","author":"Dinneen","year":"1995","journal-title":"Diabetologia"},{"key":"10.1016\/j.molmet.2017.06.012_bib3","doi-asserted-by":"crossref","first-page":"274","DOI":"10.2337\/diab.36.3.274","article-title":"Role of hyperglucagonemia in maintenance of increased rates of hepatic glucose output in type II diabetics","volume":"36","author":"Baron","year":"1987","journal-title":"Diabetes"},{"key":"10.1016\/j.molmet.2017.06.012_bib4","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1210\/jcem-64-1-106","article-title":"Documentation of hyperglucagonemia throughout the day in nonobese and obese patients with noninsulin-dependent diabetes mellitus","volume":"64","author":"Reaven","year":"1987","journal-title":"The Journal of Clinical Endocrinology and Metabolism"},{"key":"10.1016\/j.molmet.2017.06.012_bib5","doi-asserted-by":"crossref","first-page":"14972","DOI":"10.1073\/pnas.1205983109","article-title":"Metabolic manifestations of insulin deficiency do not occur without glucagon action","volume":"109","author":"Lee","year":"2012","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"key":"10.1016\/j.molmet.2017.06.012_bib6","doi-asserted-by":"crossref","first-page":"391","DOI":"10.2337\/db10-0426","article-title":"Glucagon receptor knockout prevents insulin-deficient type 1 diabetes in mice","volume":"60","author":"Lee","year":"2011","journal-title":"Diabetes"},{"key":"10.1016\/j.molmet.2017.06.012_bib7","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.2337\/diab.45.8.1076","article-title":"Evidence for a major role for glucagon in regulation of plasma glucose in conscious, nondiabetic, and alloxan-induced diabetic rabbits","volume":"45","author":"Brand","year":"1996","journal-title":"Diabetes"},{"key":"10.1016\/j.molmet.2017.06.012_bib8","doi-asserted-by":"crossref","first-page":"2503","DOI":"10.1073\/pnas.1424934112","article-title":"Glucagon receptor antibody completely suppresses type 1 diabetes phenotype without insulin by disrupting a novel diabetogenic pathway","volume":"112","author":"Wang","year":"2015","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"key":"10.1016\/j.molmet.2017.06.012_bib9","doi-asserted-by":"crossref","first-page":"2843","DOI":"10.2337\/db06-0222","article-title":"Immunoneutralization of endogenous glucagon reduces hepatic glucose output and improves long-term glycemic control in diabetic ob\/ob mice","volume":"55","author":"Sorensen","year":"2006","journal-title":"Diabetes"},{"key":"10.1016\/j.molmet.2017.06.012_bib10","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1007\/s00125-006-0481-3","article-title":"Glucagon receptor knockout mice are resistant to diet-induced obesity and streptozotocin-mediated beta cell loss and hyperglycaemia","volume":"50","author":"Conarello","year":"2007","journal-title":"Diabetologia"},{"key":"10.1016\/j.molmet.2017.06.012_bib11","doi-asserted-by":"crossref","first-page":"2615","DOI":"10.1194\/jlr.M035592","article-title":"Effects of small interfering RNA-mediated hepatic glucagon receptor inhibition on lipid metabolism in db\/db mice","volume":"54","author":"Han","year":"2013","journal-title":"Journal of Lipid Research"},{"key":"10.1016\/j.molmet.2017.06.012_bib12","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.1409638111","article-title":"Hyperglycemia in rodent models of type 2 diabetes requires insulin-resistant alpha cells","author":"Lee","year":"2014","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"key":"10.1016\/j.molmet.2017.06.012_bib13","doi-asserted-by":"crossref","first-page":"14070","DOI":"10.1073\/pnas.0806993105","article-title":"Making insulin-deficient type 1 diabetic rodents thrive without insulin","volume":"105","author":"Yu","year":"2008","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"key":"10.1016\/j.molmet.2017.06.012_bib14","doi-asserted-by":"crossref","first-page":"4813","DOI":"10.1073\/pnas.0909422107","article-title":"Leptin therapy in insulin-deficient type I diabetes","volume":"107","author":"Wang","year":"2010","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"key":"10.1016\/j.molmet.2017.06.012_bib15","doi-asserted-by":"crossref","first-page":"17391","DOI":"10.1073\/pnas.1008025107","article-title":"Leptin therapy improves insulin-deficient type 1 diabetes by CNS-dependent mechanisms in mice","volume":"107","author":"Fujikawa","year":"2010","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"key":"10.1016\/j.molmet.2017.06.012_bib16","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1016\/j.cmet.2013.08.004","article-title":"Leptin engages a hypothalamic neurocircuitry to permit survival in the absence of insulin","volume":"18","author":"Fujikawa","year":"2013","journal-title":"Cell Metabolism"},{"key":"10.1016\/j.molmet.2017.06.012_bib17","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1038\/nm.3579","article-title":"Leptin reverses diabetes by suppression of the hypothalamic-pituitary-adrenal axis","volume":"20","author":"Perry","year":"2014","journal-title":"Nature Medicine"},{"key":"10.1016\/j.molmet.2017.06.012_bib18","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1172\/JCI88477","article-title":"Mechanism for leptin's acute insulin-independent effect to reverse diabetic ketoacidosis","volume":"127","author":"Perry","year":"2017","journal-title":"Journal of Clinical Investigation"},{"key":"10.1016\/j.molmet.2017.06.012_bib19","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1210\/en.2015-1890","article-title":"Insulin knockout mice have extended survival but volatile blood glucose levels on leptin therapy","volume":"157","author":"Neumann","year":"2016","journal-title":"Endocrinology"},{"key":"10.1016\/j.molmet.2017.06.012_bib20","doi-asserted-by":"crossref","first-page":"1414","DOI":"10.2337\/db10-0958","article-title":"Leptin therapy reverses hyperglycemia in mice with streptozotocin-induced diabetes, independent of hepatic leptin signaling","volume":"60","author":"Denroche","year":"2011","journal-title":"Diabetes"},{"key":"10.1016\/j.molmet.2017.06.012_bib21","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1210\/en.2010-0890","article-title":"Leptin activates a novel CNS mechanism for insulin-independent normalization of severe diabetic hyperglycemia","volume":"152","author":"German","year":"2011","journal-title":"Endocrinology"},{"key":"10.1016\/j.molmet.2017.06.012_bib22","doi-asserted-by":"crossref","first-page":"14670","DOI":"10.1073\/pnas.1107163108","article-title":"Subcutaneous administration of leptin normalizes fasting plasma glucose in obese type 2 diabetic UCD-T2DM rats","volume":"108","author":"Cummings","year":"2011","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"key":"10.1016\/j.molmet.2017.06.012_bib23","doi-asserted-by":"crossref","first-page":"1474","DOI":"10.2337\/db10-1302","article-title":"Recombinant human leptin treatment does not improve insulin action in obese subjects with type 2 diabetes","volume":"60","author":"Mittendorfer","year":"2011","journal-title":"Diabetes"},{"key":"10.1016\/j.molmet.2017.06.012_bib24","doi-asserted-by":"crossref","first-page":"1647","DOI":"10.2337\/db10-1791","article-title":"Efficacy of metreleptin in obese patients with type 2 diabetes: cellular and molecular pathways underlying leptin tolerance","volume":"60","author":"Moon","year":"2011","journal-title":"Diabetes"},{"key":"10.1016\/j.molmet.2017.06.012_bib25","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/S0140-6736(96)03173-X","article-title":"Decreased cerebrospinal-fluid\/serum leptin ratio in obesity: a possible mechanism for leptin resistance","volume":"348","author":"Caro","year":"1996","journal-title":"Lancet"},{"key":"10.1016\/j.molmet.2017.06.012_bib26","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.addr.2012.09.037","article-title":"Liposomal drug delivery systems: from concept to clinical applications","volume":"65","author":"Allen","year":"2013","journal-title":"Advance Drug Delivery Reviews"},{"key":"10.1016\/j.molmet.2017.06.012_bib27","doi-asserted-by":"crossref","first-page":"8529","DOI":"10.1002\/anie.201203263","article-title":"Maximizing the potency of siRNA lipid nanoparticles for hepatic gene silencing in\u00a0vivo","volume":"51","author":"Jayaraman","year":"2012","journal-title":"Angewandte Chemie (International Edition in English)"},{"key":"10.1016\/j.molmet.2017.06.012_bib28","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1038\/nbt.1602","article-title":"Rational design of cationic lipids for siRNA delivery","volume":"28","author":"Semple","year":"2010","journal-title":"Nature Biotechnology"},{"key":"10.1016\/j.molmet.2017.06.012_bib29","doi-asserted-by":"crossref","first-page":"1438","DOI":"10.1073\/pnas.0237106100","article-title":"Lower blood glucose, hyperglucagonemia, and pancreatic alpha cell hyperplasia in glucagon receptor knockout mice","volume":"100","author":"Gelling","year":"2003","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"key":"10.1016\/j.molmet.2017.06.012_bib30","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.2337\/db11-1605","article-title":"Liver-specific disruption of the murine glucagon receptor produces alpha-cell hyperplasia: evidence for a circulating alpha-cell growth factor","volume":"62","author":"Longuet","year":"2013","journal-title":"Diabetes"},{"key":"10.1016\/j.molmet.2017.06.012_bib31","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1210\/en.2013-1622","article-title":"IGFBP2 is neither sufficient nor necessary for the physiological actions of leptin on glucose homeostasis in male ob\/ob mice","volume":"155","author":"Neumann","year":"2014","journal-title":"Endocrinology"},{"key":"10.1016\/j.molmet.2017.06.012_bib32","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1007\/s00125-015-3529-4","article-title":"Leptin induces fasting hypoglycaemia in a mouse model of diabetes through the depletion of glycerol","volume":"58","author":"Denroche","year":"2015","journal-title":"Diabetologia"},{"key":"10.1016\/j.molmet.2017.06.012_bib33","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1016\/j.molmet.2016.06.009","article-title":"The role of autonomic efferents and uncoupling protein 1 in the glucose-lowering effect of leptin therapy","volume":"5","author":"Denroche","year":"2016","journal-title":"Molecular Metabolism"},{"key":"10.1016\/j.molmet.2017.06.012_bib34","doi-asserted-by":"crossref","DOI":"10.1155\/2011\/416254","article-title":"Development of a nongenetic mouse model of type 2 diabetes","volume":"2011","author":"Gilbert","year":"2011","journal-title":"Experimental Diabetes Research"},{"key":"10.1016\/j.molmet.2017.06.012_bib35","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1111\/jdi.12235","article-title":"Modeling type 2 diabetes in rats using high fat diet and streptozotocin","volume":"5","author":"Skovso","year":"2014","journal-title":"Journal of Diabetes Investigation"},{"key":"10.1016\/j.molmet.2017.06.012_bib36","doi-asserted-by":"crossref","first-page":"1790","DOI":"10.2337\/db07-1615","article-title":"Glucose metabolism in\u00a0vivo in four commonly used inbred mouse strains","volume":"57","author":"Berglund","year":"2008","journal-title":"Diabetes"},{"key":"10.1016\/j.molmet.2017.06.012_bib37","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1007\/s00125-015-3794-2","article-title":"Acute disruption of glucagon secretion or action does not improve glucose tolerance in an insulin-deficient mouse model of diabetes","volume":"59","author":"Steenberg","year":"2016","journal-title":"Diabetologia"},{"key":"10.1016\/j.molmet.2017.06.012_bib38","doi-asserted-by":"crossref","first-page":"e13828","DOI":"10.7554\/eLife.13828","article-title":"Blockade of glucagon signaling prevents or reverses diabetes onset only if residual beta-cells persist","volume":"5","author":"Damond","year":"2016","journal-title":"Elife"},{"key":"10.1016\/j.molmet.2017.06.012_bib39","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1016\/j.molmet.2016.05.014","article-title":"Glucagon receptor gene deletion in insulin knockout mice modestly reduces blood glucose and ketones but does not promote survival","volume":"5","author":"Neumann","year":"2016","journal-title":"Molecular Metabolism"},{"key":"10.1016\/j.molmet.2017.06.012_bib40","doi-asserted-by":"crossref","first-page":"2376","DOI":"10.2337\/db14-1562","article-title":"Evidence that in uncontrolled diabetes, hyperglucagonemia is required for ketosis but not for increased hepatic glucose production or hyperglycemia","volume":"64","author":"Meek","year":"2015","journal-title":"Diabetes"},{"key":"10.1016\/j.molmet.2017.06.012_bib41","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1111\/dom.12672","article-title":"Effects of multiple ascending doses of the glucagon receptor antagonist PF-06291874 in patients with type 2 diabetes mellitus","volume":"18","author":"Kazierad","year":"2016","journal-title":"Diabetes, Obesity & Metabolism"},{"key":"10.1016\/j.molmet.2017.06.012_bib42","article-title":"Efficacy and tolerability of MK-0893, a glucagon receptor antagonist (GRA), in patients with type 2 diabetes (T2DM)","author":"Engel","year":"2011","journal-title":"Diabetes"},{"key":"10.1016\/j.molmet.2017.06.012_bib43","doi-asserted-by":"crossref","first-page":"1626","DOI":"10.2337\/db09-1918","article-title":"Leptin deficiency causes insulin resistance induced by uncontrolled diabetes","volume":"59","author":"German","year":"2010","journal-title":"Diabetes"},{"key":"10.1016\/j.molmet.2017.06.012_bib44","doi-asserted-by":"crossref","first-page":"E712","DOI":"10.1152\/ajpendo.00272.2014","article-title":"Leptin restores the insulinotropic effect of exenatide in a mouse model of type 2 diabetes with increased adiposity induced by streptozotocin and high-fat diet","volume":"307","author":"Sakai","year":"2014","journal-title":"American Journal of Physiology. Endocrinology and Metabolism"},{"key":"10.1016\/j.molmet.2017.06.012_bib45","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1007\/s00125-009-1258-2","article-title":"Beneficial effects of leptin on glycaemic and lipid control in a mouse model of type 2 diabetes with increased adiposity induced by streptozotocin and a high-fat diet","volume":"52","author":"Kusakabe","year":"2009","journal-title":"Diabetologia"},{"key":"10.1016\/j.molmet.2017.06.012_bib46","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1016\/j.cell.2015.05.011","article-title":"Treatment of obesity with celastrol","volume":"161","author":"Liu","year":"2015","journal-title":"Cell"},{"key":"10.1016\/j.molmet.2017.06.012_bib47","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1038\/nm.4145","article-title":"Withaferin A is a leptin sensitizer with strong antidiabetic properties in mice","volume":"22","author":"Lee","year":"2016","journal-title":"Nature Medicine"},{"key":"10.1016\/j.molmet.2017.06.012_bib48","doi-asserted-by":"crossref","first-page":"7257","DOI":"10.1073\/pnas.0706473105","article-title":"Leptin responsiveness restored by amylin agonism in diet-induced obesity: evidence from nonclinical and clinical studies","volume":"105","author":"Roth","year":"2008","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"key":"10.1016\/j.molmet.2017.06.012_bib49","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1002\/psc.2408","article-title":"Restoration of leptin responsiveness in diet-induced obese mice using an optimized leptin analog in combination with exendin-4 or FGF21","volume":"18","author":"Muller","year":"2012","journal-title":"Journal of Peptide Science"},{"key":"10.1016\/j.molmet.2017.06.012_bib50","doi-asserted-by":"crossref","first-page":"1422","DOI":"10.2337\/db13-1609","article-title":"GLP-1\/glucagon coagonism restores leptin responsiveness in obese mice chronically maintained on an obesogenic diet","volume":"63","author":"Clemmensen","year":"2014","journal-title":"Diabetes"},{"key":"10.1016\/j.molmet.2017.06.012_bib51","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1038\/nm.3115","article-title":"Hypothalamic glucagon signaling inhibits hepatic glucose production","volume":"19","author":"Mighiu","year":"2013","journal-title":"Nature Medicine"},{"key":"10.1016\/j.molmet.2017.06.012_bib52","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1038\/nrendo.2010.187","article-title":"The metabolic actions of glucagon revisited","volume":"6","author":"Habegger","year":"2010","journal-title":"Nature Reviews. Endocrinology"},{"key":"10.1016\/j.molmet.2017.06.012_bib53","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1152\/physrev.00025.2016","article-title":"The new biology and pharmacology of glucagon","volume":"97","author":"Muller","year":"2017","journal-title":"Physiological Reviews"}],"container-title":["Molecular Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2212877817301941?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2212877817301941?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,8,31]],"date-time":"2018-08-31T09:53:53Z","timestamp":1535709233000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2212877817301941"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,10]]},"references-count":53,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2017,10]]}},"alternative-id":["S2212877817301941"],"URL":"https:\/\/doi.org\/10.1016\/j.molmet.2017.06.012","relation":{},"ISSN":["2212-8778"],"issn-type":[{"value":"2212-8778","type":"print"}],"subject":[],"published":{"date-parts":[[2017,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Lipid nanoparticle delivery of glucagon receptor siRNA improves glucose homeostasis in mouse models of diabetes","name":"articletitle","label":"Article Title"},{"value":"Molecular Metabolism","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.molmet.2017.06.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 The Authors. Published by Elsevier GmbH.","name":"copyright","label":"Copyright"}]}}